Tag Directory / HEALTHCARE     showing 41–60 of 261



Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus / OncoDaily

oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance


Friday, February 27, 2026, 11:22 pm / permalink 19912 / 6 stories in 11 days


UHS posts 11.5% operating margin in 2025 as net income jumps 30% / Beckers

Andrew Cass / beckershospitalreview - King of Prussia, Pa.-based Universal Health Services recorded a net income of $1.5 billion in 2025, up from $1.1 billion in 2024, according to its Feb. 25 financial report. Eight things to know: 1. The for-profit system reported an operating income of $2 …

#healthcare #publichealth #governmentpolicy #behavioralhealth #hospitaloperations #healthcarefinance


Friday, February 27, 2026, 11:25 am / permalink 19887 / 10 stories in 11 days


Cancer blood test fails to catch disease earlier in major study / Medical Express

medicalxpress - A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it.

#healthcare #publichealth #governmentpolicy #biotech #medicaldevices #oncology


Thursday, February 26, 2026, 7:24 pm / permalink 19851 / 7 stories in 12 days


Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial / Endpoints

Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment


Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 13 days


More Research, Less Cancer: £250m raised to transform the future of cancer research / Cancer Research UK

Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology


Tuesday, February 24, 2026, 1:24 pm / permalink 19675 / 53 stories in 14 days


FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026 / OncoDaily

oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda


Tuesday, February 24, 2026, 12:25 pm / permalink 19669 / 6 stories in 14 days


ChatGPT Health performance in a structured test of triage recommendations / Nature

Ashwin Ramaswamy / nature - Nature Medicine, Published online: 23 February 2026; doi:10.1038/s41591-026-04297-7A stress test of ChatGPT Health triage revealed missed high-risk emergencies and inconsistent activation of suicide-crisis safeguards, raising safety concerns for consumer-…

#healthcare #publichealth #governmentpolicy #fda #digitalhealth #medicaldevices


Tuesday, February 24, 2026, 11:25 am / permalink 19660 / 18 stories in 14 days


Gilead to acquire cell therapy manufacturer for $7.8B / Beckers

Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology


Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 15 days


Justice Department sues OhioHealth over alleged anticompetitive insurer contracts / Healthcare Dive

Sydney Halleman / healthcaredive - The DOJ filed a lawsuit last week accusing OhioHealth of leveraging its market power to force insurers to include its providers in their networks.

#healthcare #governmentpolicy


Monday, February 23, 2026, 2:23 pm / permalink 19594 / 7 stories in 15 days


Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO

esmo - Findings from the KEYNOTE-905/EV-303 study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology


Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 16 days


Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily

oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology


Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 16 days


Brain injury is almost ten times more common in unhoused people. Addressing it is key to reducing homelessness / Medical Express

medicalxpress - On any given night, 60,000 people in Canada will go to sleep homeless. Research estimates that more than half of them have had a brain injury at one point in their lives, most of them being injured before becoming homeless. An estimated 22.5% live with mo…

#healthcare #publichealth #governmentpolicy


Saturday, February 21, 2026, 6:23 pm / permalink 19543 / 4 stories in 17 days


‘You’re not the Lone Ranger’ anymore: Medical education evolves for team-based care / Beckers

Paige Twenter / beckershospitalreview - As U.S. healthcare increasingly adopts team-based care, medical schools are working to prepare students for future care delivery models, according to a Feb. 18 article from the Association of American Medical Colleges. Team-based care, or a coordinated ba…

#healthcare #publichealth #fda #digitalhealth #medicaldevices


Saturday, February 21, 2026, 12:22 pm / permalink 19529 / 3 stories in 17 days


Optum unveils Value Connect, its AI-powered tool to support value-based care / Fierce

fiercehealthcare - Optum is rolling out a new AI tool that aims to address some of the key barriers to value-based care, from data fragmentation to administrative burden.

#healthcare #digitalhealth


Saturday, February 21, 2026, 10:22 am / permalink 19522 / 21 stories in 18 days


A novel C. diff vaccine shows promise / Beckers

Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety


Saturday, February 21, 2026, 7:21 am / permalink 19520 / 2 stories in 18 days


Novartis signs macrocyclic deal with Unnatural Products for $100M upfront / Endpoints

Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment


Saturday, February 21, 2026, 6:22 am / permalink 19517 / 2 stories in 18 days


Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA / MedCity

Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda


Saturday, February 21, 2026, 6:22 am / permalink 19516 / 5 stories in 18 days


Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks / Nature

Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.

#healthcare #publichealth #biotech #drugdevelopment #fda #medicaldevices


Saturday, February 21, 2026, 2:22 am / permalink 19513 / 13 stories in 18 days


Hims to buy Australia’s Eucalyptus for $240M upfront in global push / Endpoints

Ngai Yeung / endpoints - In a bid to build out its global presence, Hims is buying Australian digital health company Eucalyptus in a deal worth $240 million upfront. The deal announced Thursday morning would allow Hims to launch in ...

#healthcare #mergersandacquisitions #corporatetakeover #digitalhealth


Saturday, February 21, 2026, 1:23 am / permalink 19510 / 5 stories in 18 days


CDC confirms 910 measles cases in 2026; South Carolina remains hardest hit / Beckers

Paige Twenter / beckershospitalreview - Six weeks into 2026, the CDC has confirmed 910 measles cases. If the pace of transmission continues, this year could far outpace the 2,280 cases detected across the U.S. in 2025, as 2026’s total is already 40% of 2025’s. The hardest-hit state is South Car…

#healthcare #publichealth #cdc #vaccinesafety


Saturday, February 21, 2026, 1:22 am / permalink 19508 / 11 stories in 18 days


Back to Top


HEALTHCARE Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.